This is a significant clinical catalyst that validates pemvidutide's potential in AUD, a large unmet market (~28M US adults). The stock should re-rate on the data strength and FDA registrational endpoint hits. Watch for the End-of-Phase 2 meeting outcome and any partnership or financing announcements to fund the PERFORMA Phase 3 MASH trial and RESTORE ALD trial.
Price Chart
Executive Summary
Altimmune announced positive topline results from the RECLAIM Phase 2 trial of pemvidutide in alcohol use disorder (AUD), meeting the primary endpoint with a statistically significant reduction in heavy drinking days (p=0.0014) and hitting key secondary endpoints recognized by the FDA as registrational. The company plans to request an End-of-Phase 2 meeting with the FDA, advancing pemvidutide's pipeline across AUD, MASH, and ALD. This is a material clinical catalyst for the stock, though the company remains pre-revenue and faces significant capital needs to fund Phase 3 development.
Key Facts
- RECLAIM Phase 2 trial met primary endpoint: pemvidutide 2.4 mg reduced heavy drinking days per week by -1.45 vs placebo (LS mean difference, p=0.0014)
- 64.4% of pemvidutide patients achieved a 2-level reduction in WHO Risk Drinking Levels vs 34.8% for placebo (p=0.0049), a registrational endpoint
- 42.2% of pemvidutide patients achieved zero heavy drinking days vs 17.4% for placebo (p=0.0066), also a registrational endpoint
- Placebo-adjusted body weight reduction of 9.1% at 24 weeks (p<0.0001), with no evidence of plateauing
- Pemvidutide was generally well-tolerated; 10% study-drug-related discontinuations vs 0% placebo; one possibly-related SAE (hyponatremia)
- Company plans to request an End-of-Phase 2 meeting with the FDA based on these results
- Pemvidutide has FDA Fast Track designation for AUD and MASH, and Breakthrough Therapy designation for MASH
Financial Impact
No financial data in filing; company is pre-revenue. Positive Phase 2 data supports potential regulatory path and partnership value, but Phase 3 costs remain unfunded.
Risk Factors
- Company needs substantial additional capital to fund Phase 3 development (PERFORMA MASH trial, RESTORE ALD trial), which may cause dilution
- Phase 2 results may not be predictive of larger Phase 3 outcomes; FDA may require additional studies
- Competition from other GLP-1 and dual agonist programs for AUD and MASH
- Pemvidutide GI tolerability (44% nausea, 18% vomiting) could be a competitive disadvantage vs oral or better-tolerated agents
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001326190-26-000044 |
| Document: alt-20260728x8k.htm | 0001326190-26-000044 |
| Document: 0001326190-26-000044-index-headers.html | 0001326190-26-000044 |
| Document: 0001326190-26-000044-index.html | 0001326190-26-000044 |
| Document: 0001326190-26-000044.txt | 0001326190-26-000044 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 29, 2026 27d ago | 8-K | $2.97 $2.67 | ▼ −10.10% | ▼ −12.05% | $2.09 (−29.63%) |
Aug 12, 2026 10w ago | 8-K | $2.93 $3.12 | ▲ +6.48% | ▲ +6.93% | $2.09 (−28.67%) |
Aug 12, 2026 10w ago | Press Release | $2.93 $3.12 | ▲ +6.48% | ▲ +6.93% | $2.09 (−28.67%) |
Aug 6, 2026 11w ago | Institutional Cluster | $3.01 $2.88 | ▼ −4.32% | ▼ −5.53% | $2.09 (−30.56%) |
Aug 5, 2026 11w ago | Press Release | $3.03 $2.93 | ▼ −3.30% | ▼ −3.65% | $2.09 (−31.02%) |
Aug 3, 2026 12w ago | Press Release | $3.00 $3.05 | ▲ +1.67% | ▼ −0.36% | $2.09 (−30.33%) |
Jul 28, 2026 12w ago | 8-K | $2.99 $3.00 | ▲ +0.33% | ▼ −1.93% | $2.09 (−30.10%) |
May 28, 2026 21w ago | Press Release | $3.07 $2.87 | ▼ −6.51% | ▼ −6.47% | $2.09 (−31.92%) |
May 27, 2026 21w ago | Press Release | $2.98 $2.90 | ▼ −2.68% | ▼ −3.89% | $2.09 (−29.87%) |
May 13, 2026 23w ago | 8-K | $3.02 $2.74 | ▼ −9.27% | ▼ −8.11% | $2.09 (−30.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers